DCGO · Docgo Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $322.20M | $616.56M | $624.29M | $440.52M | $94.09M | - |
| Cost of Revenue | - | - | - | $523.95M | - | - |
| Gross Profit | - | - | - | ($83.43M) | - | - |
| R&D | $13.56M | $11.59M | $10.86M | $5.38M | $1.19M | - |
| SG&A | $133.45M | $138.76M | $137.15M | $103.40M | $34.91M | - |
| Total Operating Expenses | $500.23M | $587.87M | $609.23M | $418.68M | $108.85M | - |
| D&A | $15.66M | $15.88M | $2.31M | $10.57M | $5.51M | - |
| Operating Income | ($178.03M) | $28.69M | $15.05M | $21.83M | ($14.76M) | - |
| Interest Expense | - | - | - | $117.7K | $15.8K | - |
| Income Tax | $8.87M | $14.39M | $6.36M | ($7.96M) | $167.4K | - |
| Net Income | $19.99M | $19.99M | $6.86M | $34.58M | ($14.80M) | - |
| EPS - Basic | ($1.84) | $0.20 | $0.07 | $0.34 | ($0.25) | - |
| EPS - Diluted | ($1.84) | $0.18 | $0.06 | $0.34 | ($0.25) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $51.02M | $89.24M | $59.29M | $157.34M | $175.54M | $878.7K |
| Accounts Receivable | $92.89M | $210.90M | $262.08M | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $11.11M | $28.36M | $19.83M | $21.58M | $15.83M | $11.7K |
| Current Assets | $152.40M | $304.49M | $338.87M | $271.08M | $256.03M | $1.05M |
| Total Assets | $217.10M | $455.62M | $490.45M | $393.28M | $309.60M | $116.07M |
| Current Liabilities | $67.49M | $121.81M | $170.12M | $100.16M | $57.88M | $159.8K |
| Long-term Debt | $183.8K | $5.2K | $41.6K | - | $142.7K | - |
| Total Liabilities | $91.23M | $140.44M | $185.28M | $114.35M | $82.55M | $4.18M |
| Stockholders' Equity | $144.01M | $320.92M | $300.79M | $273.23M | $219.58M | $5.00M |
| Retained Earnings | ($183.80M) | ($1.40M) | ($21.39M) | ($28.97M) | ($63.56M) | ($148.8K) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $34.45M | $70.34M | ($64.22M) | $28.87M | ($10.65M) | - |
| Investing Cash Flow | ($39.08M) | ($10.87M) | ($29.88M) | ($38.45M) | ($6.04M) | - |
| Financing Cash Flow | ($50.82M) | ($24.15M) | $1.12M | ($6.18M) | ($812.1K) | - |
| CapEx | $4.54M | $3.83M | $7.58M | $3.20M | $4.36M | - |
| Free Cash Flow | $29.91M | $66.50M | ($71.81M) | $25.67M | ($15.02M) | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | -18.9% | - | - |
| Operating margin | -55.3% | 4.7% | 2.4% | 5.0% | -15.7% | - |
| EBITDA margin | -50.4% | 7.2% | 2.8% | 7.4% | -9.8% | - |
| Net margin | 6.2% | 3.2% | 1.1% | 7.9% | -15.7% | - |
| Free cash flow margin | 9.3% | 10.8% | -11.5% | 5.8% | -16.0% | - |
| FCF / Net income | 1.50 | 3.33 | -10.47 | 0.74 | 1.01 | - |
| R&D / Revenue | 4.2% | 1.9% | 1.7% | 1.2% | 1.3% | - |
| SG&A / Revenue | 41.4% | 22.5% | 22.0% | 23.5% | 37.1% | - |
| Effective tax rate | 30.7% | 41.9% | 48.1% | -29.9% | - | - |
| Return on assets | 9.2% | 4.4% | 1.4% | 8.8% | -4.8% | - |
| Return on equity | 13.9% | 6.2% | 2.3% | 12.7% | -6.7% | - |
| Return on invested capital | -85.5% | 5.2% | 2.6% | - | -5.3% | - |
| Liquidity | ||||||
| Current ratio | 2.26 | 2.50 | 1.99 | 2.71 | 4.42 | 6.55 |
| Quick ratio | 2.26 | 2.50 | 1.99 | 2.71 | 4.42 | 6.55 |
| Cash ratio | 0.76 | 0.73 | 0.35 | 1.57 | 3.03 | 5.50 |
| Leverage | ||||||
| Debt / Equity | 0.00 | 0.00 | 0.00 | - | 0.00 | - |
| Debt / Assets | 0.00 | 0.00 | 0.00 | - | 0.00 | - |
| Debt / EBITDA | - | 0.00 | 0.00 | - | - | - |
| Interest coverage | - | - | - | 185.5x | -931.2x | - |
| Equity multiplier | 1.51 | 1.42 | 1.63 | 1.44 | 1.41 | 23.21 |
| Liabilities / Assets | 0.42 | 0.31 | 0.38 | 0.29 | 0.27 | 0.04 |
| Efficiency | ||||||
| Asset turnover | 1.48 | 1.35 | 1.27 | 1.12 | 0.30 | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 105d | 125d | 153d | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | 15d | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | 23.6x | 93.2x | 20.8x | - | - |
| P / B | 0.6x | 1.4x | 2.0x | 2.7x | 2.5x | - |
| P / S | 0.3x | 0.8x | 0.9x | 1.7x | 5.8x | - |
| EV / EBITDA | - | 8.4x | 30.6x | 17.6x | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -47.7% | -1.2% | 41.7% | 368.2% | - | - |
| Revenue CAGR (3y) | -9.9% | 87.1% | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | - | 90.6% | -31.0% | - | - | - |
| Net income growth (YoY) | 0.0% | 191.5% | -80.2% | - | - | - |
| EPS growth (YoY) | - | 200.0% | -82.4% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -55.0% | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -55.1% | 6.7% | 10.1% | 24.4% | 4291.6% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$322.20M totalTransportation Services Segment$200.77M · 62.3%
Mobile Health Services Segment$121.43M · 37.7%
Geographic
$322.20M totalUS$268.25M · 83.3%
GB$53.94M · 16.7%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-0.84
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
6/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Services-Health Services
Comparing DocGo Inc. against the 5 most active filers in the same SIC group.